Cartalax (AED peptide)
Bioregulatory Tripeptide · Cartilage & Connective Tissue Support
Overview
Synthetic tripeptide developed by Professor Vladimir Khavinson, supporting cartilage, connective tissue, and cellular regeneration through proliferation markers and apoptosis pathway modulation.
Modulates cell proliferation, suppresses apoptosis, affects fibroblast activity, reduces senescence markers, and influences extracellular matrix preservation.
Clinical efficacy shown in osteochondrosis, osteoarthritis, and osteoporosis treatment.
Supports cartilage maintenance and joint function.
Supports bone and connective tissue healing.
Mechanism
Synthetic tripeptide developed by Professor Vladimir Khavinson, supporting cartilage, connective tissue, and cellular regeneration through proliferation markers and apoptosis pathway modulation.
Modulates cell proliferation, suppresses apoptosis, affects fibroblast activity, reduces senescence markers, and influences extracellular matrix preservation.
Clinical efficacy shown in osteochondrosis, osteoarthritis, and osteoporosis treatment.
Research areas
- Synthetic tripeptide developed by Professor Vladimir Khavinson, supporting cartilage, connective tissue, and cellular regeneration through proliferation markers and apoptosis pathway modulation.
- Modulates cell proliferation, suppresses apoptosis, affects fibroblast activity, reduces senescence markers, and influences extracellular matrix preservation.
- Clinical efficacy shown in osteochondrosis, osteoarthritis, and osteoporosis treatment.
- Supports cartilage maintenance and joint function.
- Supports bone and connective tissue healing.
Research notes
- No reported side effects in Russian clinical use when taken properly
- Well-tolerated in elderly patients
- Digestive upset (rare with proper administration)
- No improvement after 3 months
- Pregnancy and breastfeeding
Literature
- Cartalax increases fibroblast proliferation while suppressing apoptosis. Theoretical concern exists regarding uncontrolled cell growth, but Russian clinical practice spanning decades shows no documented malignancy risk. Avoid use in active cancer; for healthy individuals, cyclic use (1-3 months on, breaks between)…
Questions
How does Cartalax help cartilage if cartilage doesn't have blood vessels to deliver it?
Cartalax works through systemic effects on fibroblasts and gene expression. Once in circulation, it reaches fibroblasts throughout connective tissue, stimulating collagen production and suppressing matrix-degrading enzymes like MMP-9. This systemic fibroblast activation supports cartilage maintenance and collagen…
Can Cartalax reverse osteoarthritis or just prevent progression?
Russian clinical studies show efficacy in established osteoarthritis, osteochondrosis, and osteoporosis treatment. However, 'reverse' is overstated—Cartalax supports tissue repair and slows degeneration better than it rebuilds severely damaged cartilage. Results are best when cartilage damage is moderate, not advanced.